The AHA Aug. 28 urged the Drug Enforcement Administration to reconsider its proposed 2019 aggregate production quotas for certain controlled substances, which the agency said would reduce manufacturing quotas for six frequently misused opioids by an average 10 percent. “Hospitals and other providers are currently facing critical shortages of a number of injectable opioid medications for which that the DEA recommends quota reductions, including morphine, hydromorphone, and fentanyl,” AHA said in a letter to DEA. “These decreases would exacerbate these already dire shortages.” AHA said its request is “specific to these injectable medopications and does not extend to other dosage forms or opioid products.” Comments are due Sept. 19.

Related News Articles

Headline
The Centers for Medicare & Medicaid Services today released an updated tool for viewing and comparing opioid prescribing rates over time and across regions.
Headline
The National Academy of Medicine Action Collaborative on Countering the U.S. Opioid Epidemic last week held a webinar on the work it will undertake over the…
Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tenn., today convened a hearing on “Managing Pain During the Opioid Crisis”…
Headline
The Centers for Medicare…
Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…